Lenvima
Drug - Lenvima™ (lenvatinib capsules) [Eisai Inc.]
November 2015
Therapeutic area - Oncology
Approval criteria
The patient must meet all of the following criteria:
- Has a diagnosis of differentiated thyroid cancer
- The disease is locally recurrent or metastatic
- The disease is refractory to radioactive iodine treatment
- No longer responds to TSH suppressive therapy
Quantity limit
- 10 mg daily dose = 30 capsules per 30 days
- 14 mg daily dose = 60 capsules per 30 days
- 20 mg daily dose = 60 capsules per 30 days
- 24 mg daily dose = 90 capsules per 30 days
Billing
LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.
Questions?
MHCP Provider Call Center 651-431-2700 or 800-366-5411